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INTRODUCTION
Most cancer patients die from advanced, metastatic
disease. Because surgery and external irradiation are
the best prospects for treating localized disease
(although both have also been applied to limited
treatment of metastatic disease), systemic chemo-
therapy—and more recently, immunotherapy—are
the mainstays of treating cancer that has become
disseminated. Systemic chemotherapy is accompa-
nied by dose-limiting toxicities to various organ
systems, particularly the rapid proliferating cells of
the oral and intestinal mucosa, bone marrow, and
hair follicles, and agents that target antibodies are
usually less potent, cause infusion or flu-like reac-
tions, and are most effective in combination with
cytotoxic drugs 1,2.
Another class of agents that combines the fore-
going properties has emerged in the form of radiola-
belled antibodies, which harness the ability of
antibodies against cancer antigens to localize to can-
cer cells, and the cytotoxicity of the radiation carried
by the antibodies. In 1978, I named this method, then
in its infancy, “radioimmunotherapy” 3. The last quar-
ter-century has witnessed development in all aspects
of this therapy, such as choice of antibody and anti-
body form, selection of therapeutic radionuclide, con-
jugation chemistry, and tumour target and clinical
setting. These aspects have been reviewed else-
where 4–7, and so they will not be the principal focus
of this article. Instead, I will summarize the status,
including problems and prospects, for the applica-




The experience with radioimmunotherapy has been
different for hematopoietic disease and for solid can-
cers, with non-Hodgkin lymphoma (NHL) therapy
being the use for which the first radioimmuno-
conjugate products gained regulatory approvals and
started into clinical use 8–11. The two approved prod-
ucts both consist of murine antibodies against CD20,
with added naked antibody protein—either murine
or chimeric (human/mouse) monoclonal antibodies
(mAbs). At doses delivered to tumour of less than
20 Gy (usually around 10 Gy), therapeutic efficacy
is superior to that of naked mAb counterparts 12,13
and even comparable to the effects of complicated
regimens of cytotoxic drugs or to the use of naked
mAbs in combination with chemotherapy, as reported
for  NHL patients with advanced disease 8–11. Those
findings support the view that radioimmunotherapy
can be effective if used in the proper setting and if
sufficient radiation is targeted.
In the case of the less radiosensitive solid tu-
mours, the best results have been seen in the settings
of minimal disease or of compartmental, or regional,
application so as to optimize the dose of radiation
delivered. Many antibodies bearing a variety of ra-
dionuclides are being tested clinically against diverse
cancers (Table I), and some have in fact shown en-
couraging targeting and some evidence of tumour
response. However, only in the setting of minimal
disease, such as an adjuvant setting, or with the use
of an indirect method of radioimmunotherapy called
“pre-targeting” has evidence of clinical efficacy been
reported.
The adjuvant case involves the use of 131I-label-
led, humanized, anti-carcinoembryonic antigen (CEA)
mAb after salvage resection of colorectal metastases
to the liver, where a doubling of median survival to
68 months was reported during long-term follow-
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up 14. In the pre-targeting mode, the tumour is first
targeted with a bi-specific antibody. One arm of the
antibody binds to the tumour antigen (for example,
CEA); the second arm targets a peptide that is given in
a second step to deliver the radioactivity to the tu-
mour through binding to a tumour-localized anti-
body 7,15–17. In a study of patients with CEA-expressing
medullary thyroid carcinoma, improved survival was
found in the patients receiving the 131I–peptide after
pre-targeting when those patients had a high tumour-
marker (calcitonin) doubling time; patients not given
radioimmunotherapy or lacking the increased calci-
tonin doubling time showed significantly poorer out-
come 18. Still other methods of pre-targeting, not
involving bi-specific antibodies, have also shown
evidence of therapeutic efficacy when given as com-
partmental therapy in brain cancers 19.
Finally, even directly radiolabelled antibodies
have shown therapeutic promise in preclinical and
clinical studies involving regional or compartmental
administration, such as in brain cancers 20 and also in
peritoneal spread of ovarian and colorectal can-
cers 21–23. However, as discussed elsewhere 24, a piv-
otal, randomized trial of adjuvant intraperitoneal
radioimmunotherapy in ovarian cancer with a radio-
labelled murine anti-Muc-1 mAb failed to show any
efficacy advantage 25.
CONCLUSION
The variety of studies and approaches are, in my view,
encouraging, because in certain settings, solid tu-
mours may yet prove to be responsive to radio-
immunotherapy—particularly to the improved
indirect pre-targeted methods. Radioimmunotherapy
with first-generation conjugates are effective in the
management of lymphomas, but adoption of the new
modality in patients with NHL has been challenged by
TABLE I Approved or investigational radiolabelled antibodies for the treatment of cancer a
Indication Agent
Hematologic malignancies
Non-Hodgkin lymphoma 90Y–Ibritumomab tiuxetan b
131I–Tositumomab b
90Y–Epratuzumab anti-CD22 IgG
T-Cell lymphomas, non-Hodgkin and Hodgkin lymphomas 90Y–Anti-Tac IgG
Leukemia 131I–BC8 anti-CD45 IgG
213Bi–HuM195 anti-CD33 IgG
188Re– or 90Y–anti-CD66 IgG
Solid malignancies
Colorectal cancer 90Y–T84.66 anti-CEA IgG
131I– and 90Y–labetuzumab (anti-CEA IgG)
125I– and 131I–A33 IgG
131I–CC49-DCH2
90Y–Biotin pre-targeted by CC49–StAv fusion protein
Ovarian cancer 177Lu– and 90Y–CC49
131I–Anti-CEA IgG
90Y–Biotin pre-targeted by biotinylated mAb cocktail
90Y–Hu3S193
Prostate cancer 177Lu–J591 IgG
Pancreatic cancer 90Y–PAM4 IgG
Lung cancer 131I–chTNT
Hepatocellular cancer 131I–Hepama-1 IgG
90Y–hAFP IgG




90Y–BC2 and BC4 antitenascin
90Y–Biotin pre-targeted by biotin–BC4
125I–425 IgG
CNS or leptomeningeal cancer 131I–8H9 IgG
Medulloblastoma 131I–3F8 IgG
Head and neck cancers 86Re–Bivatuzumab IgG
Medullary thyroid cancer 131I–Hapten pre-targeted by anti-CEA bsmAb
a Adapted from Goldenberg et al. 17, with permission of the publisher.
b Approved by the U.S. Food and Drug Administration; all others are under investigation.
IgG = immunoglobulin G; CEA = carcinoembryonic antigen.RADIOIMMUNOTHERAPY OF METASTATIC CANCER
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the unprecedented success of a single antibody,
rituximab, especially in combination with chemo-
therapy 1,2,26,27. However, the current state of therapy
in most solid cancers does not provide a similar ad-
vantage—particularly with such treatment-refractory
neoplasms as lung, pancreatic, biliary, hepatocellu-
lar, and hormone-resistant prostatic carcinomas—and
so any improvement in response attributable to
radioimmunotherapy, either alone or combined with
drugs or non-cytotoxic immunotherapy, would be
welcome.
Other evidence indicates that any tumour will
respond if given enough radiation, but the challenge,
as in chemotherapy, is to make irradiation tumour-
selective, sparing normal organs from toxicity. In
terms of delivering radiation or even drugs, the best
prospect is to conjugate them to selectively targeting
antibodies, as discussed elsewhere 1,28,29. Unfortu-
nately, because most phase I and II trials with new
agents, including radioimmunoconjugates, involve
patients with refractory and advanced disease—an
application that is contrary to the paradigm that the
efficacy of radioimmunotherapy is inversely related
to size of the target tumours 4–7,30,31—the literature is
replete with failed efforts to show tumour shrinkage
with one or even more administrations of radio-
immunoconjugates. As clinical testing moves to ad-
dress minimal disease, compartmental therapy, and
the improved delivery achieved with pre-targeting
strategies, I remain optimistic that the prospects for
cancer radioimmunotherapy will improve.
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